CRE25-040: A Case of Stage IV NSCLC With MET Exon 14 Mutation With Durable Response to MET Inhibitor Following Cessation of Therapy Due to Toxicity: Insights for Treatment Strategies
"CRE25-040: A Case of Stage IV NSCLC With MET Exon 14 Mutation With Durable Response to MET Inhibitor Following Cessation of Therapy Due to Toxicity: Insights for Treatment Strategies" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Emmeline C. Academia (ORCID: https://orcid.org/0000-0001-7514-1754)
- Page Widick
- Chanmi Lee (ORCID: https://orcid.org/0000-0002-2951-1344)
Institutions
- Beth Israel Deaconess Medical Center (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7155
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00